{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:12:22Z","timestamp":1776309142004,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI122001"],"award-info":[{"award-number":["R21AI122001"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30AI168386"],"award-info":[{"award-number":["P30AI168386"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW007124"],"award-info":[{"award-number":["D43TW007124"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are scarce data on the clinical outcomes of persons retreated with new\/companion anti-tuberculosis (TB) drugs for multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). We sought to evaluate the efficacy and safety of bedaquiline and delamanid containing regimens among patients with and without prior exposure to the new\/companion drugs (bedaquiline, delamanid, linezolid, clofazimine, and fluoroquinolones).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective cohort study among patients with pulmonary MDR\/RR-TB in Georgia who received bedaquiline and delamanid combination as a part of a salvage regimen from November 2017 to December 2020 in a programmatic setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 106 persons with a median age of 39.5 years, 44 (41.5%) were previously treated with new\/companion TB drugs. Patients with prior exposure to new\/companion drugs had higher rates of baseline resistance compared to those without exposure to new\/companion TB drugs (bedaquiline 15.2% vs 1.8%, linezolid 22.2% vs 16.7%). Sputum culture conversion rates among patients exposed and not exposed to new\/companion drugs were 65.9% vs 98.0%, respectively (P &amp;lt; .001). Among patients with and without prior new\/companion TB drug use, favorable outcome rates were 41.0% and 82.3%, respectively (P &amp;lt; .001). Treatment adherence in 32 (30.2%) patients was \u226480%. Five of 21 patients (23.8%) who had a baseline and repeat susceptibility test had acquired bedaquiline resistance. QTC\/F prolongation (&amp;gt;500\u2005ms) was rare (2.8%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Prior exposure to new\/companion TB drugs was associated with poor clinical outcomes and acquired drug resistance. Tailoring the TB regimen to each patient's drug susceptibility test results and burden of disease and enhancing adherence support may improve outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad694","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T18:42:52Z","timestamp":1699987372000},"page":"1043-1052","source":"Crossref","is-referenced-by-count":10,"title":["Impact of Prior Tuberculosis Treatment With New\/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis"],"prefix":"10.1093","volume":"78","author":[{"given":"L","family":"Mikiashvili","sequence":"first","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases , Tbilisi , Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-4996","authenticated-orcid":false,"given":"R R","family":"Kempker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Disease, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T S","family":"Chakhaia","sequence":"additional","affiliation":[{"name":"School of Public Health, Georgia State University , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Bablishvili","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases , Tbilisi , Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Avaliani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases , Tbilisi , Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Lomtadze","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases , Tbilisi , Georgia"},{"name":"Department of Medicine, David Tvildiani Medical University , Tbilisi , Georgia"},{"name":"Department of Medicine, The University of Georgia , Tbilisi , Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"Schechter","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Disease, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kipiani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases , Tbilisi , Georgia"},{"name":"Department of Medicine, David Tvildiani Medical University , Tbilisi , Georgia"},{"name":"Department of Medicine, The University of Georgia , Tbilisi , Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"2024041017090299000_ciad694-B1","author":"WHO","year":"2021"},{"key":"2024041017090299000_ciad694-B2","author":"WHO","year":"2013"},{"key":"2024041017090299000_ciad694-B3","author":"WHO","year":"2014"},{"key":"2024041017090299000_ciad694-B4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1183\/13993003.00637-2016","article-title":"First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"key":"2024041017090299000_ciad694-B5","doi-asserted-by":"crossref","first-page":"1702550","DOI":"10.1183\/13993003.02550-2017","article-title":"Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia","volume":"51","author":"Guglielmetti","year":"2018","journal-title":"Eur Respir J"},{"key":"2024041017090299000_ciad694-B6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1473-3099(18)30100-2","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024041017090299000_ciad694-B7","doi-asserted-by":"crossref","first-page":"1900811","DOI":"10.1183\/13993003.00811-2019","article-title":"Final treatment outcomes of delamanid-containing regimens in patients with MDR-\/XDR-TB in South Korea","volume":"54","author":"Mok","year":"2019","journal-title":"Eur Respir J"},{"key":"2024041017090299000_ciad694-B8","doi-asserted-by":"crossref","first-page":"1702467","DOI":"10.1183\/13993003.02467-2017","article-title":"Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea","volume":"51","author":"Kim","year":"2018","journal-title":"Eur Respir J"},{"key":"2024041017090299000_ciad694-B9","doi-asserted-by":"crossref","first-page":"1800934","DOI":"10.1183\/13993003.00934-2018","article-title":"Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review","volume":"52","author":"Pontali","year":"2018","journal-title":"Eur Respir J"},{"key":"2024041017090299000_ciad694-B10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijtb.2019.02.006","article-title":"Early efficacy and safety of bedaquiline and delamanid given together in a \u201cSalvage Regimen\u201d for treatment of drug-resistant tuberculosis","volume":"66","author":"Sarin","year":"2019","journal-title":"Indian J Tuberc"},{"key":"2024041017090299000_ciad694-B11","doi-asserted-by":"crossref","first-page":"1901181","DOI":"10.1183\/13993003.01181-2019","article-title":"A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis","volume":"55","author":"Olayanju","year":"2020","journal-title":"Eur Respir J"},{"key":"2024041017090299000_ciad694-B12","volume-title":"Consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment, 2022 update","author":"WHO","year":"2022"},{"key":"2024041017090299000_ciad694-B13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1473-3099(22)00007-X","article-title":"Implications of bedaquiline-resistant tuberculosis","volume":"22","author":"Mishra","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024041017090299000_ciad694-B14","doi-asserted-by":"crossref","first-page":"e3496","DOI":"10.1093\/cid\/ciaa1577","article-title":"One step forward: successful end-of-treatment outcomes of drug-resistant TB patients who received concomitant bedaquiline and delamanid in Mumbai, India","volume":"73","author":"Das","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024041017090299000_ciad694-B15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/cid\/ciac176","article-title":"Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and other second-line drugs","volume":"75","author":"Huerga","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024041017090299000_ciad694-B16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2024041017090299000_ciad694-B17","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2024041017090299000_ciad694-B18","first-page":"2336","article-title":"Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline or delamanid containing regimens","volume":"71","author":"Kempker","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024041017090299000_ciad694-B19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.5588\/ijtld.19.0444","article-title":"Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study","volume":"24","author":"Mikiashvili","year":"2020","journal-title":"Int J Tuber Lung Dis"},{"key":"2024041017090299000_ciad694-B20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1473-3099(22)00689-2","article-title":"Tuberculosis recovery in Georgia: implementing more by 24","volume":"23","author":"Kiria","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"11 Suppl 2","key":"2024041017090299000_ciad694-B21","first-page":"S265","article-title":"Active tuberculosis drug safety monitoring and management results in the country of Georgia","volume":"22","author":"Adamashvili","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024041017090299000_ciad694-B22","author":"WHO","year":"2021"},{"key":"2024041017090299000_ciad694-B23","author":"WHO","year":"2014"},{"key":"2024041017090299000_ciad694-B24","author":"WHO","year":"2018"},{"key":"2024041017090299000_ciad694-B25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","article-title":"Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study","volume":"22","author":"Ismail","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024041017090299000_ciad694-B26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cid\/ciz074","article-title":"Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment","volume":"69","author":"Polsfuss","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024041017090299000_ciad694-B27","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/jac\/dkx094","article-title":"Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region","volume":"72","author":"Zimenkov","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024041017090299000_ciad694-B28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/AAC.00239-17","article-title":"Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis","volume":"61","author":"Xu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024041017090299000_ciad694-B29","doi-asserted-by":"crossref","first-page":"1902383","DOI":"10.1183\/13993003.02383-2019","article-title":"Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients","volume":"55","author":"Nimmo","year":"2020","journal-title":"Eur Respir J"},{"key":"2024041017090299000_ciad694-B30","doi-asserted-by":"crossref","first-page":"e3391","DOI":"10.1093\/cid\/ciaa1002","article-title":"Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China","volume":"73","author":"Liu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024041017090299000_ciad694-B31","doi-asserted-by":"crossref","first-page":"2100621","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur Respir J"},{"key":"2024041017090299000_ciad694-B32","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis","volume":"373","author":"Bloemberg","year":"2015","journal-title":"N Engl J Med"},{"key":"2024041017090299000_ciad694-B33","doi-asserted-by":"crossref","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2024041017090299000_ciad694-B34","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jac\/dkab505","article-title":"Delamanid or pretomanid? A solomonic judgement!","volume":"77","author":"Mudde","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024041017090299000_ciad694-B35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2024041017090299000_ciad694-B36","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, delamanid, linezolid and clofazimine for treatment of pre-extensively drug-resistant tuberculosis","volume":"76","author":"Padmapriyadarsini","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"11 Suppl 2","key":"2024041017090299000_ciad694-B37","first-page":"S426","article-title":"High rate of successful outcomes treating RR-TB with a delamanid-bedaquiline regimen in BEAT Tuberculosis: an interim analysis","volume":"26","author":"Conradie","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024041017090299000_ciad694-B38","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024041017090299000_ciad694-B39","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort [published correction appears in Clin Infect Dis. 2023; 76(4):779]","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024041017090299000_ciad694-B40","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciac876","article-title":"Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"76","author":"Holmgaard","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad694\/54126272\/ciad694.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/4\/1043\/57209242\/ciad694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/4\/1043\/57209242\/ciad694.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T18:13:05Z","timestamp":1712772785000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/4\/1043\/7420195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,14]]},"published-print":{"date-parts":[[2024,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad694","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,15]]},"published":{"date-parts":[[2023,11,14]]}}}